Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
4 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
5 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
6 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
7 African trypanosomiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
8 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
13 Alcoholic liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
14 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
15 Allograft rejection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
16 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
17 Alzheimer disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
18 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
19 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
20 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
21 Amoebiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
22 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
23 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
24 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
25 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
26 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
27 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
28 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
29 Antifolate resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
30 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
31 Antigen processing and presentation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
32 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
33 Apoptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
34 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Asthma 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
36 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
37 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
38 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
39 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
40 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
41 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
42 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
43 Bladder cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
44 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
45 Breast cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
46 Breast cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
47 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
48 C-type lectin receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
49 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
50 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
51 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
52 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
53 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
54 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
55 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
56 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
57 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
58 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
59 Calcium signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
60 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
61 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
62 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
63 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
64 Cellular senescence 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
65 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
66 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
67 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
68 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
69 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
70 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
71 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
72 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
73 Chagas disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
74 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
75 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
76 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
77 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
78 Chemical carcinogenesis - receptor activation 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
79 Chemical carcinogenesis - receptor activation 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
80 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
81 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
82 Chemical carcinogenesis - receptor activation 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
83 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
84 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
85 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
86 Complement and coagulation cascades 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
87 Coronavirus disease - COVID-19 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
88 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
89 Cytokine-cytokine receptor interaction 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
90 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
91 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
92 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
93 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
94 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
95 Dilated cardiomyopathy 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
96 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
97 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
98 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
99 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
100 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
101 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
102 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
103 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
104 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
105 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
106 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
107 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
108 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
109 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
110 Epstein-Barr virus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
111 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
112 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
113 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
114 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
115 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
116 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
117 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
118 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
119 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
120 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
121 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
122 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
123 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
124 Focal adhesion 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
125 FoxO signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
126 Gap junction 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
127 Gap junction 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
128 Gap junction 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
129 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
130 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
131 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
132 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
133 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
134 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
135 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
136 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
137 GnRH secretion 💬
 1件: ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
138 GnRH secretion 💬
 1件: ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
139 GnRH secretion 💬
 1件: ESR2 💬 D08559 💬 Tamoxifen 3件:  2 , 113, 227 💬
140 Graft-versus-host disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
141 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
142 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
143 Hematopoietic cell lineage 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
144 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
145 Hepatitis B 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
146 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
147 Hepatitis C 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
148 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
149 Herpes simplex virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
150 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
151 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
152 HIF-1 signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
153 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
154 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
155 Human cytomegalovirus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
156 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
157 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
158 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
159 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
160 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
161 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
162 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
163 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
164 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
165 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
166 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
167 Human papillomavirus infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
168 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
169 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
170 Human papillomavirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
171 Human T-cell leukemia virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
172 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
173 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
174 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
175 Hypertrophic cardiomyopathy 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
176 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
177 IL-17 signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
178 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
179 Inflammatory bowel disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
180 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
181 Influenza A 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
182 Influenza A 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
183 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
184 Insulin resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
185 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
186 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
187 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
188 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
189 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
190 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
191 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
192 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
193 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
194 Legionellosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
195 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
196 Leishmaniasis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
197 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
198 Lipid and atherosclerosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
199 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
200 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
201 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
202 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
203 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
204 Malaria 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
205 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
206 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
207 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
208 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
209 MAPK signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
210 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
211 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
212 MAPK signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
213 Measles 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
214 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
215 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
216 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 6件: 13, 34, 85, 87, 227, 280 💬
217 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
218 mTOR signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
219 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
220 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
221 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
222 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
223 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
224 Necroptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
225 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
226 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
227 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
228 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
229 Neuroactive ligand-receptor interaction 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 7件: 46, 70, 215, 227, 274, 288, 299 💬
230 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
231 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
232 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
233 NOD-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
234 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
235 Non-alcoholic fatty liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
236 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
237 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
238 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
239 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
240 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
241 Osteoclast differentiation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 5件: 28, 51, 85, 227, 331 💬
242 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
243 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 34件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164,